Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 01, 2005 (Vol. 25, No. 17)

A-1 Database on Vaccines and News About Vaccines

URL:www.vaccines.com
  • Well-organized information
  • Dumb title
Here’s a site with a lot of information and a rare opportunity—it’s up for sale. Billed as providing “up-to-the-minute news about vaccines and an annotated database of vaccine resources on the Internet,” vaccines.com serves a very diverse audience. On the opening page, one can view information aimed at adults, parents, practitioners, and researchers. Other sections deal with journals on epidemiology, immunization, or pediatrics and a listing of relevant organizations in the field. Most of the content at the site is in the form of links which are organized in an intelligent manner. I found it very easy to navigate to find what I wanted, and the Search page and Site Index page assisted further. There’s a lot to like here, save for the rather ugly title. Perhaps a column reader will buy vaccines.com and fix that as well.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »